Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

By C. Fakhry, W. Westra, Sigui Li, A. Cmelak, J. Ridge, H. Pinto, A. Forastiere, M. Gillison. Journal of the National Cancer Institute, 2008

2,711 citations recorded by the source corpus.

Subfields: Otorhinolaryngology, Periodontics, Surgery

View Paper: https://www.semanticscholar.org/paper/a4951800fc5459d9bb48d8cbdbaa0bf8a0456c90

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Otorhinolaryngology

1. S. Marur
2. A. Forastiere

In Surgery

1. A. Jemal
2. J. Ferlay
3. S. Marur
4. F. Bray

Citations in the corpus

• The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012 (2017, background): “HR-HPV positivity impacts on survival, with HR-HPV–related oral cavity cancers associated with a better prognosis.(51,52) Thus, given the prevalence and impact of various factors on the risk of oral cavity cancers, early detection and prevention are important.”
• PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. (2013, background): “Although these tumors frequently have aggressive histopathological features (2), the presence of HPV DNA is a favorable prognostic factor with regard to recurrence and survival (3-5).”
• Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? (2017, background): “Finally HPV-positive patients do well independently of treatment choice, as long as conforms to the standard of care [2,3,7].”
• Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. (2016, background): “org significantly on the basis of tumor site, tumor tissue HPV status, and overall stage.(11) This review will focus on recent advances in diagnosis, distinct molecular and clinical phenotypes of HNSCC, treatment advances in early, locally advanced, and metastatic HNSCC, risk stratification for OPSC”
• Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma (2023, background): “HPV-positive HNSCC is now staged differently due to the large disparity in survival [51].”
• Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation (2023, background): “It would have been expected that a positive HPV status is associated with prolonged overall and progression-free survival, as well as improved treatment response, as it was shown in large-scale, prospective, randomized clinical trials [13,14].”